赵连友教授简介.ppt

抵消副作用的联合用药 药物都有程度不同的副作用，用另外一种药物可以抵消其不良反应，增加患者服药依从性，达到控制血压的目的。 平衡低剂量利尿剂的代谢影响 安博维 HCTZ 尿酸: ↓ 防止血钾丢失 尿酸: ↑ 血钾: ↓ 安博诺 为什么选用厄贝沙坦和利尿剂联合? 小 结 高血压病优化联合用药治疗是提高高血压控制率重要的方法，合理的联合用药是保护脏器重要的措施，优化联合用药是降低高血压致残率及死亡率的重要策略。 海捷亚?ISH患者耐受性显著优于氨氯地平 M Volpe et al Clinical Therapeutics Vol25 No.5 2003 1469-1489 * p 0.001 + p =0.002 * + * N=432 N=425 不良反应发生率( %) 减少不良反应 * * Major clinical trials have demonstrated that patients typically needed treatment with multiple antihypertensive agents to get to, and stay at, BP goal. The number of antihypertensive agents required for BP control in many patients typically averages 2?4, with co-morbid conditions (such as kidney disease or diabetes mellitus) imposing greater drug requirement.1,2 For example, in the Hypertension Optimal Treatment (HOT) study, an average of 3.3 drugs were required to attain a diastolic BP goal of 80 mmHg, and in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), most patients were taking at least two antihypertensive agents by the end of the trial.2,3 In the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, patients were receiving initial treatment with fixed-dose combinations, i.e. 2-drug combination. The interim 6-month results have shown that BP control rates achieved in this study are higher than any other multinational trial to date.4 References 1. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. The cycle repeats. Drugs 2002;62:443?62. 2. Bakris GL, et al. The importance of blood pressure control in the patient with diabetes. Am J Med 2004;116(5A):30S–8S. 3. Dahl?f B, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre rand